9/14/2012 7:43:50 AM
Newron Pharmaceuticals SpA (NWRN)’s proposed acquisition of NeuroNova AB is too expensive and may derail the introduction of Newron’s most promising drug, according to the company’s largest shareholder. The takeover will distract Newron from ensuring its experimental treatment for Parkinson’s disease, safinamide, gets to market as soon as possible, said Mauro Saponelli, the chief financial officer of Zambon Company SpA, which owns 12 percent of Newron. Zambon and other investors are scheduled to vote on the deal at a meeting next week.
comments powered by